Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation.

View/ Open
Date
2019-08-08Author
Dalton, WB
Helmenstine, E
Walsh, N
Gondek, LP
Kelkar, DS
Read, A
Natrajan, R
Christenson, ES
Roman, B
Das, S
Zhao, L
Leone, RD
Shinn, D
Groginski, T
Madugundu, AK
Patil, A
Zabransky, DJ
Medford, A
Lee, J
Cole, AJ
Rosen, M
Thakar, M
Ambinder, A
Donaldson, J
DeZern, AE
Cravero, K
Chu, D
Madero-Marroquin, R
Pandey, A
Hurley, PJ
Lauring, J
Park, BH
Type
Journal Article
Metadata
Show full item recordAbstract
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.
Collections
Subject
Cell Line, Tumor
Animals
Humans
Mice
Neoplasms
Serine
Glycine
Neoplasm Proteins
Phosphoproteins
Proteome
Xenograft Model Antitumor Assays
Energy Metabolism
Mutation
Phosphoglycerate Dehydrogenase
Transcriptome
Cellular Reprogramming
RNA Splicing Factors
Research team
Functional Genomics
Language
eng
License start date
2019-08-08
Citation
The Journal of clinical investigation, 2019, 129 (11), pp. 4708 - 4723
Publisher
AMER SOC CLINICAL INVESTIGATION INC